Abstract
OPINION article Front. Immunol., 12 January 2015Sec. Inflammation Volume 5 - 2014 | https://doi.org/10.3389/fimmu.2014.00685
Highlights
Tumor heterogeneity has been recognized as one of the main factors for cancer therapy failure, and has just started to be dissected using next-generation sequencing (NGS) approaches [4]
NGS-derived studies have often been conducted using single fragments/biopsies of primary tumors, and fail to reflect the global tumor heterogeneity, dynamics, and drug sensitivities, likely to change during tumor evolution and treatment
Most of these have been focused on the characterization of the cargo of extracellular vesicles (EVs) in different types of cancer, using either conditioned media of cancer cell lines, or unique samples from cancer patients’ body fluids
Summary
Tumor heterogeneity has been recognized as one of the main factors for cancer therapy failure, and has just started to be dissected using next-generation sequencing (NGS) approaches [4]. EVs can be detected in biological fluids such as plasma, serum, ascites, or urine, and provide excellent minimally invasive biomarker candidates to monitor cancer patients’ progression, prognosis, and treatment efficacy [10, 11].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
